Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.70 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | ARG2 | P78540 | 1/20 | 0.52 |
| ▸ | TOP1 | P11387 | 1/20 | 0.42 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | AGXT | P21549 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL95186 | 1.00 | MAOB (0.70) | MAOBCA1CA2ARG2TOP1 | |
| SCHEMBL9110389 | 0.83 | MAOB (0.61) | MAOBCA1CA2ARG2TOP1 | |
| SCHEMBL9110392 | 0.83 | MAOB (0.61) | MAOBCA1CA2ARG2TOP1 | |
| SCHEMBL155055 | 0.83 | MAOB (1.00) | MAOBCA1CA2ARG2TOP1 | |
| SCHEMBL155054 | 0.83 | MAOB (1.00) | MAOBCA1CA2ARG2TOP1 | |
| SCHEMBL1524697 | 0.83 | MAOB (1.00) | MAOBCA1CA2ARG2TOP1 | |
| SCHEMBL9063783 | 0.81 | LTA4H (0.52) | MAOBCA1CA2TSHR | |
| SCHEMBL628859 | 0.78 | MAOB (0.78) | MAOBCA1CA2ARG2TOP1 | |
| Allylbenzene SCHEMBL833722 | 0.78 | — | — | |
| SCHEMBL462351 | 0.78 | MAOB (0.78) | MAOBCA1CA2ARG2TOP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 475 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0831812-B1 | METHODS AND COMPOSITIONS FOR STIMULATING NEURITE GROWTH | VERTEX PHARMA (US) | 2005-12-07 | — | — | EP | claimed |
| US-5201936-A | Substituted thieno[3,2-b]pyran-5,7-diones | BAYER AKTIENGESELLSCHAFT (DE) | 1993-04-13 | — | — | US | claimed |
| EP-0483582-A1 | Thieno[3,2-b]pyranones, process for their preparation, intermediates, their use in combatting parasites, their use as herbicides and plantgrowth regulators | BAYER AG (DE) | 1992-05-06 | — | — | EP | claimed |
| EP-0205834-B1 | 7-THIABICYCLOHEPTANE SUBSTITUTED ETHERS | E.R. Squibb & Sons, Inc. (US) | 1990-10-31 | — | — | EP | claimed |
| US-4198503-A | 3-Carbamoyl substituted-7-ureido substituted cephalosporins | BEECHAM GROUP LIMITED (GB) | 1980-04-15 | — | — | US | claimed |
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-15 | — | — | US | disclosed |
| CN-107027309-B | Antibacterial agent | 昆士兰大学 | 2021-10-01 | — | — | CN | disclosed |
| US-10947271-B2 | Antibacterial agents | THE UNIVERSITY OF QUEENSLAND (AU) | 2021-03-16 | — | — | US | disclosed |
| US-20200281951-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-09-10 | — | — | US | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-10603331-B2 | Method of treating disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-03-31 | — | — | US | disclosed |
| EP-0180188-A2 | A composition for increasing the anti-cancer activity of an anti-cancer compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-07 | — | — | EP | disclosed |
| EP-0125248-A1 | INSECTICIDAL SUBSTITUTED-BIPHENYLMETHYL OXIME ETHERS | FMC Corporation (US) | 1984-11-21 | — | — | EP | disclosed |
| WO-1984001772-A1 | INSECTICIDAL SUBSTITUTED-BIPHENYLMETHYL OXIME ETHERS | FMC CORP (US) | 1984-05-10 | — | — | WO | disclosed |
| US-4434182-A | Insecticidal substituted-biphenylmethyl oxime ethers | FMC CORPORATION (US) | 1984-02-28 | — | — | US | disclosed |
| US-4411912-A | Insecticidal isovaleric acid esters | ZOECON CORPORATION (US) | 1983-10-25 | — | — | US | disclosed |
| US-4312982-A | BACTERICIDES | BEECHAM GROUP LIMITED (GB) | 1982-01-26 | — | — | US | disclosed |
| US-4243819-A | Substituted amino acids | ZOECON CORPORATION (US) | 1981-01-06 | — | — | US | disclosed |
| US-4198503-A | 3-Carbamoyl substituted-7-ureido substituted cephalosporins | BEECHAM GROUP LIMITED (GB) | 1980-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | MAOB 3664/4885CA1 890/4885CA2 170/4885 |
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | CRH, MC2R, HTR3C | MAOB 131/4885CA1 380/4885CA2 1380/4885 |
| US-20200281951-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | MC2R, SLC6A2, CRH | MAOB 49/4885CA1 3525/4885CA2 4091/4885 |
| US-10603331-B2 | Method of treating disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine | MC2R, PNMT, SLC6A2 | MAOB 50/4885CA1 2616/4885CA2 3522/4885 |
| US-10947271-B2 | Antibacterial agents | VNN1, ASNS, AAAS | MAOB 3041/4885CA1 3931/4885CA2 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.